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What is the central question of this study? 
Adrenomedullin in the rostral ventrolateral medulla (RVLM) increases sympathetic 
activity. Given that adrenomedullin is released during hypoxia, we explored its antagonism 
and agonism in the RVLM after chronic intermittent hypoxia (CIH) exposure.  
What is the main finding and its importance? 
We found that CIH exposure sensitizes adrenomedullin-dependent mechanisms in the 
RVLM, supporting its role as a sympathoexcitatory neuromodulator. Our data identify a 
novel mechanism for the generation of sympathetic overdrive and hypertension associated 
with hypoxia, providing a potential guidance on new therapeutic approaches for controlling 
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Abstract 
Adrenomedullin in the rostral ventrolateral medulla (RVLM) has been shown to 
increase sympathetic activity whereas the antagonism of its receptors inhibited this 
autonomic activity lowering blood pressure in conditions of hypertension. Given that hypoxia 
is a stimulant for releasing adrenomedullin, we hypothesized that the presence of this peptide 
in the RVLM associated with chronic intermittent hypoxia (CIH) would cause sympathetic 
overdrive. Juvenile male rats (50-55 g) submitted to CIH (6% oxygen every 9 min, 8 h/day 
for 10 days) were studied in an arterially perfused in situ preparation where sympathetic 
activity was recorded. In control rats (n=6), exogenously applied adrenomedullin in the 
RVLM raised baseline sympathetic activity when combined with episodic activation of 
peripheral chemoreceptors (KCN 0.05%, 5 times every 5 min). This sympathoexcitatory 
response was markedly amplified in rats previously exposed to CIH (n=6). The antagonism of 
adrenomedullin receptors in the RVLM caused a significant reduction in sympathetic activity 
in CIH group (n=7), but not in controls (n=8). The transient reflex evoked 
sympathoexcitatory response to peripheral chemoreceptor stimulation was not affected by 
either adrenomedullin or adrenomedullin receptor antagonism in the RVLM of control and 
CIH rats. Our findings indicate that CIH sensitizes the sympathoexcitatory networks within 
the RVLM to adrenomedullin, supporting its role as an excitatory neuromodulator when 
intermittent hypoxia is present. These data reveal novel state-dependent mechanistic insights 
into the generation of sympathetic overdrive and provide potential guidance on possible 
unique approaches for controlling sympathetic discharge in diseases such as sleep apnoea and 
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INTRODUCTION 
Persistent sympathetic overactivity is an established common feature of numerous 
diseases (Julius & Nesbitt, 1996; Canale et al., 2013) yet its aetiology remains enigmatic. 
Unequivocally, understanding the mechanisms involved in both raising and sustaining levels 
of sympathetic nerve activity (SNA) remains crucial for designing novel therapeutic 
strategies and addressing unmet clinical need. One such need is sleep apnoea. Sleep apnoea 
prevalence is up to 15% in middle-aged adults and is characterized by repetitive bouts of 
oxygen desaturations (apnoea-hypopnoea index  15) that triggers hypertension caused 
mainly through persistent over activation of the sympathetic nervous system (Simpson et al., 
2013; Arnardottir et al., 2016; McNicholas, 2017). Because patients remain hypertensive 
during the day, the chronic intermittent hypoxia (CIH) that occurs at night induces plasticity 
within neural circuits controlling sympathetic activity. Understanding what these sensitisation 
mechanisms are that produce long-term facilitation of sympathetic activity is clearly 
important for controlling sympathetic activity and hypertension in sleep apnoea but may have 
wider implications for all diseases where sympathetic overdrive is rife. However, given that 
continuous positive airway pressure requires >5.5 hours per night to reduce sympathetic 
activity and blood pressure and as a result is poorly tolerated (Fava et al., 2014; Furlan et al., 
2015) this reinforces the need to understand sympathetic activity generation during CIH. This 
challenge was the main aim of this study. 
We have considered the peptide adrenomedullin acting on the sympathoexcitatory 
neural networks of the rostral ventrolateral medulla (RVLM) – a major region for generation 
of sympathetic activity destined for the cardiovascular system (Guertzenstein & Silver, 1974; 
Ross et al., 1984b; Sun et al., 1988). Adrenomedullin is a 52-amino acid peptide, initially 
isolated from human pheochromocytoma and is known to be a potent peripheral vasorelaxant 
peptide (Kitamura et al., 1993; Nuki et al., 1993). It is synthesised and secreted from both 
vascular smooth muscle and endothelial cells (Minamino et al., 2002). Intriguingly, the 
International Consortium for Blood Pressure Genome-Wide Association et al. (2011) 
identified from a genome wide association study that adrenomedullin and one of its receptors 
were variants in a meta-analysis of blood pressure whereas Verweij et al. (2013) reported 
genetic variants in the genes encoding pre-pro-adrenomedullin. These variants were 
interpreted to functionally affect the vascular system. However, adrenomedullin has also been 
found within the brain (Sakata et al., 1994; Ueta et al., 2001; Serrano et al., 2002b) and in 
contrast to its function in the periphery of lowering blood pressure (Ishiyama et al., 1993; 
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Kitamura et al., 1993; Nuki et al., 1993), it caused hypertension (Saita et al., 1998; Shan & 
Krukoff, 2001b; Xu & Krukoff, 2004) via excitation of pre-sympathetic pre-motor neurones 
located in the RVLM (Fan et al., 2006). Most relevant to this study is that adrenomedullin 
synthesis and release is known to be triggered by ischemia and hypoxia in both the periphery 
(Minamino et al., 2002; Belloni et al., 2004) and within the brain (Serrano et al., 2002a). 
Given that both acute (Dick et al., 2007; Xing & Pilowsky, 2010; Lemes et al., 2016) and 
chronic intermittent hypoxia (Fletcher et al., 1992; Zoccal et al., 2008; Zoccal et al., 2009a) 
cause long-term facilitation of sympathetic activity and hypertension, we tested the 
hypothesis that combining exposure of rats to CIH with adrenomedullin in the RVLM would 
sensitize sympathoexcitatory neural networks leading to persistent sympathetic overdrive.  
MATERIALS AND METHODS 
Ethical Approval 
All procedures were carried out according to the UK Animals (Scientific Procedures) 
Act 1986, under licence to the Home Office and were approved by the University of Bristol, 
the University of São Paulo and the São Paulo State University animal welfare committees 
(Protocols 019/2006 and 18/2014). Methods and experiments also conform to the principles 
and regulations of journal policy and regulations on animal experimentation (Grundy, 2015). 
Experiments were conducted on weaned male Wistar rats (50-55 g) bred within the 
University of São Paulo and the São Paulo State University’s animal facilities and housed 
with controlled temperature (23  2 ºC) with humidity control (55  10% v/v), and a 12/12h 
light/dark period (lights on at 07:00 h) and ad libitum access to food and water.  
Animal studies 
The rats were exposed to CIH as previously described (Zoccal et al., 2008). Briefly, 
the animals were housed in collective cages (maximum of 5 animals per cage) and 
maintained inside chambers equipped with gas injectors as well as sensors of O2, CO2, 
humidity and temperature, at controlled conditions of temperature (22±1 °C) and humidity 
(55±10 % v/v). The CIH protocol consisted of 5 minutes of normoxia (FiO2 of 20.8% v/v) 
followed by 4 minutes of pure N2 injection into the chamber to reduce the FiO2 to 6.2-6% 
(v/v), remaining at this level for 40 seconds. After this hypoxic period, pure O2 was injected 
to return the FiO2 back to 20.8% (v/v). This 9-minute cycle was repeated 8 hours a day (from 
9:30 am to 5:30 pm) for 10 days. During the remaining 16 hours, the animals were 
maintained at a FiO2 of 20.8% (v/v). The injections of N2 and O2 (White Martins, São Carlos, 
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Brazil) were regulated by a solenoid valve system controlled by a computerized system 
(Oxycycler, Biospherix, USA). In an identical chamber in the same room, the control rat 
group was exposed to a FiO2 of 20.8% (v/v) 24 hours a day for 10 days. The control rats were 
also exposed to a similar valve noise due to the frequent injection of O2 to maintain the FiO2 
at 20.8% (v/v). In both CIH and control chambers, the gas injections were performed at the 
upper level of the chamber in order to avoid direct jets of gas impacting on the animals, 
which could cause stress. 
Arterially perfused in situ juvenile rat preparation  
After CIH or normoxia exposure, rats were surgically prepared as originally described 
(Paton, 1996) to obtain the in situ preparations. In brief, rats were anesthetized using 
isoflurane (5% v/v). A deep level of anaesthesia was assessed by a failure to respond to a 
noxious pinch of either a paw or the tail and an absence of a corneal reflex. The rats were 
then transected below the diaphragm, exsanguinated (which resulted in euthanasia) and their 
upper body submerged in ice-cooled Ringer solution. The cranium was opened and rats 
decerebrated at the pre-collicular level. The preparation was skinned, transferred to a 
recording chamber and a double-lumen catheter was inserted into the descending aorta. One 
lumen was used to deliver perfusate pumped using a roller pump (Watson Marlow 505S). 
The perfusate was an isosmotic Ringer solution containing in mM: NaCl 120, NaHCO3 24, 
KCl 3, CaCl2 2.5, MgSO4 1.25, KH2PO4 1.25, glucose 10, plus an oncotic agent 
(polyethylene glycol, 1.5% w/v; Sigma-UK), gassed with carbogen (95% v/v O2 and 5% CO2 
v/v), warmed to 32°C, pH 7.3 after carbogenation, and filtered using a nylon screen (pore size: 
25 μm). The second lumen of the catheter was used to monitor aortic perfusion pressure, 
which was maintained in the range of 60-70 mmHg by adjusting the rate flow to 21-25 
mL.min
-1
 and by adding vasopressin to the perfusate (0.6 - 1.2 nM, Sigma, St. Louis, MO, 
USA). When necessary, additional increments in the flow rate or AVP in the perfusate were 
applied (10-20 % of the initial values) in some preparations after 60-90 min to maintain in the 
perfusion pressure levels throughout experiments and to avoid any pressure-related changes. 
The head of the preparation was fixed by ear bars and a nasal clamp so that the dorsal surface 
of the brainstem was positioned horizontally. The cerebellum was removed to enhance access 
to the dorsal brainstem for intraparenchymal microinjections. The left phrenic nerve (PN) 
was isolated and its activity recorded from the cut central end using a glass suction bipolar 
electrode held in a 3-D micromanipulator. Rhythmic, ramping PN activity gave a continuous 
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physiological index of preparation viability. After respiratory-related movements re-
commenced, a neuromuscular blocker (vecuronium bromide, 40 μg ml
−1
, Cristália, Itapira, 
BR) was added to the perfusate to mechanically stabilize the preparation. Sympathetic nerve 
activity was recorded from the thoracic sympathetic chain (tSN) using a bipolar glass suction 
electrode. All nerve signals were AC-amplified (P511, Grass Technologies, Middleton, 
USA), band-pass filtered (0.1−3 kHz), rectified and displayed as a moving average using a 50 
ms time constant. At the end of each experiment the background electrical noise was 
measured after application of lidocaine (2%) to the sympathetic chain; this level was 
subtracted from the integrated signal.  
Microinjections into the RVLM 
Using glass micropipettes (20-30 m tip diameter), microinjections of adrenomedullin 
(100 fmol/100 nl, American Peptides, Sunnyvale, USA) or AM 22-52 (adrenomedullin type 1 
and 2 receptor antagonist, 100 pmol/100 nl, American Peptides) were made bilaterally in the 
RVLM using the following coordinates: 400-500 µm rostral to the rostral pole of area 
postrema, 1600-1700 µm lateral to the midline and 3.8-4.0 mm ventral to the dorsal surface 
of the brainstem. The concentrations of agonist and antagonist were determined based on 
previous studies demonstrating the effects of adrenomedullin in the RVLM of anaesthetised 
rats (Xu & Krukoff, 2004). The volume microinjected was determined by viewing the 
movement of the meniscus through a binocular microscope fitted with a pre-calibrated 
eyepiece reticule. The RVLM microinjection sites were identified physiologically by 
microinjection of L-glutamate (1 nmol/100 nl) to evoke an increase in SN activity (Moraes et 
al., 2012). Vehicle controls were performed using saline (100 nl). In some experiments, 
fluorescent latex microbeads were added to the glutamate solution to also allow histological 
verification of the injection sites (see below). 
Experimental protocol 
Initially baseline PN and tSN activities were recorded for 20-30 min and then 
peripheral arterial chemoreceptors were stimulated using potassium cyanide (KCN, 0.05% 
w/v, 50 µl; injected into a side port of the arterial perfusion catheter). We a priori determined 
that this dose was sub-maximal and supra-threshold. After the RVLM was functionally 
identified (increases in tSN to glutamate), bilateral microinjections of adrenomedullin were 
performed into the RVLM of both control and CIH treated rats. Next, baseline PN and tSN 
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activities were monitored for 40 min to evaluate any effects of adrenomedullin in both control 
and CIH groups. Following this period, a second bilateral microinjection of adrenomedullin 
was delivered into the RVLM, followed by five sequential intra-arterial injections of KCN 
given every 5 min, to episodically stimulate peripheral chemoreceptors. After the last 
injection of KCN, the PN and tSN activities were examined for up to 40 min to examine any 
persistent changes in these parameters induced by the combination of adrenomedullin in the 
RVLM and repetitive peripheral chemoreceptor stimulation. A separate group of CIH in situ 
preparations were submitted to the same experimental protocol, except that they received 
bilateral microinjections of saline in the RVLM. 
In other groups of control and CIH in situ preparations, we assessed the contribution 
of adrenomedullin-related mechanisms to the maintenance of sympathetic activity in control 
and CIH groups. Baseline and KCN-induced PN and tSN activities were initially evaluated as 
aforementioned and then bilateral microinjection of adrenomedullin receptor antagonist (AM 
22-52) were performed in the RVLM. Next, baseline tSN and PN activities of control and 
CIH preparations were measured at 10, 30 and 60 min after microinjections in the RVLM. 
Immediately after each baseline measurement, KCN injections were performed to verify the 
tSN and PN responses to carotid body chemoreceptor stimulation following AM 22-52 
microinjections in the RVLM.  
Histological processing  
At the end of the study, brainstems were gently removed and placed in fixative 
solution (4% w/v paraformaldehyde) for 3 days, followed by cryoprotection in 20% sucrose 
for an additional 2-3 days. Coronal sections of 50 m were performed to histologically 
confirm the sites of injection into RVLM (Leica DM IRB, Weztlar, Germany) either by the 
identification of the pipette track in the brain tissue or by verification of fluorescent latex 
microbeads (Lumafluor, New City, NY, USA) that were contained in the L-glutamate 
solution (1% w/v).  
 
Data analyses 
All data were digitized (5 kHz sample rate) using a CED 1401 A–D interface (CED, 
Cambridge Electronic Design, Cambridge, UK) and a computer running Spike 2 software 
(version 7, CED) with custom-written scripts for data acquisition and off-line analyses. Data 
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analyses were performed on rectified and smoothed signals. PN activity was analyzed by its 
burst amplitude (µV) and frequency (calculated by the time interval between consecutive 
bursts and expressed as bursts per minute, bpm). Average sympathetic activity (µV) was 
determined as the mean values over 1-3 min epochs. Moreover, to evaluate possible changes 
in the sympathetic activity due to alterations in respiratory activity, especially in the CIH rats 
that exhibited strengthened respiratory-sympathetic coupling (Zoccal et al., 2008; Molkov et 
al., 2011), we also analysed the average values of baseline tSN activity (V) during the 
different respiratory phases (using the PN activity as a reference): inspiration (INSP, 
coincident with PN bursts), expiratory stage 1 (E1) or post-inspiration (the first 2/3 of 
expiratory phase) and expiratory stage 2 (E2) (remaining 1/3 of expiratory phase). Alterations 
in PN and tSN activities induced by either adrenomedullin or by AM 22-52 in the RVLM of 
control and CIH rats were expressed in raw units and as percentage change relative to 
baseline (before microinjections). During peripheral chemoreflex stimulation, changes in PN 
frequency was expressed as the difference between peak response and respective baseline. 
The tSN response to KCN was determined by an increase in the area under the curve of the 
integrated signal, and the changes were expressed as percentage difference from respective 
baseline.  
The results were expressed as mean ± standard deviation of mean (SD) and were 
compared using unpaired Student t-test or two-way ANOVA with repeated measures, 
followed by Tukey or Dunnett post-hoc test, depending on the experimental protocol. The 
confidence level (confidence interval, CI) was set as 95% and the differences were 
considered statistically significant when P<0.05. Graphic operations and statistical analyses 
were performed using GraphPad Prism software (version 8, GraphPad, La Jolla, USA). 
RESULTS 
Sympathetic nerve activity characteristics after CIH 
 In situ preparations of CIH rats exhibited elevated baseline sympathetic outflows 
associated with enhanced respiratory-related modulation of sympathetic activity (Figure 1A) 
as described previously (Zoccal et al., 2008). In both control and CIH in situ preparations 
(n=6/each), tSN activity displayed an increasing activity during the INSP phase reaching a 
peak during late-INSP or beginning of E1 (Figure 1A). In the CIH group, the levels of tSN 
during INSP (120.755.1 vs control 64.710.9 µV, Figure 1B, P=0.0029) and E2 phases 
(80.222.0 vs control 50.86.7 µV, Figure 1B, P=0.0390) were significantly higher 
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compared to the control group as found before (Zoccal et al., 2008). No statistical differences 
between rat groups were noted for both the tSN during E1 phase (76.322.2 vs control 
52.55.8 µV, Figure 1B, P=0.3903) and baseline PN burst frequency (228 vs control 185 
bpm, P>0.9999). 
Adrenomedullin in RVLM causes minor changes on baseline sympathetic activity of in situ 
preparations of CIH rats  
Acutely, either unilateral or bilateral RVLM microinjections of adrenomedullin 
promoted inconsistent changes in the PN and tSN activities recorded from in situ preparations 
of both rat groups. In the control group (n=6), bilateral adrenomedullin microinjections into 
the RVLM were ineffective in promoting long-term changes in baseline tSN activity (Figure 
2). At 20 and 40 min after microinjections of adrenomedullin, the levels of mean tSN activity 
(6.97.6 and 5.511 % from baseline; Figure 3A), as well as the average changes in tSN 
during INSP (-1.612.5 and -7.221.0 % from baseline), E1 (12.98.2 and 12.921.6 % from 
baseline) and E2 phases (9.710.3 and 10.921.1 % relative to baseline) were not different 
from baseline (P>0.05; Figure 3B). In in situ preparations of CIH group (n=6), bilateral 
adrenomedullin microinjections in the RVLM caused a transient increase in tSN activity 
during E2 phase at 20 min (43.974.4 % from baseline, P=0.05; Figure 3C), but not in the 
other respiratory phases (INSP: 8.07.3 and E1: 28.323.9 % from baseline, P>0.05; Figure 
3C). This adrenomedullin-induced increase in sympathetic activity during E2 phase was not 
enough to significantly elevate mean tSN levels (26.717.9 % from baseline, P=0.070; Figure 
3A). Forty minutes after microinjections, mean (17.413.0 % from baseline, Figure 3A) and 
respiratory-related tSN activity (INSP: 2.421.4, E1: 26.044.6 and E2: 23.928.4 % from 
baseline; Figure 3C) of CIH rats were similar to baseline levels (P>0.05). CIH animals that 
received microinjections of equivalent volumes of vehicle (saline) in the RVLM (n=5) did 
not exhibit significant changes (P>0.05) in the levels of mean tSN (4.05.8 and 7.46.1 % 
from baseline, respectively 20 and 40 min after microinjections; Figure 3A) and in tSN 
activity during INSP and E1 phases (INSP: 0.23.6 and 2.95.9 % from baseline, E1: 0.92.1 
and 4.93.8 % from baseline, respectively 20 and 40 min after injections; Figure 3D), 
although a modest increase was noted during E2 phase (10.810.4 and 14.415.6 % from 
baseline, respectively 20 and 40 min after injections, P<0.0428; Figure 3D).  
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With respect to PN activity, microinjections of adrenomedullin in the RVLM of 
control group did not cause significant changes in burst amplitude (-6.74.8 and -6.06.3 % 
from baseline, respectively 20 and 40 min after microinjections, P>0.9999; Figure 4A), but 
increased burst frequency after 20 (2511 bpm, P=0.0601; Figure 4B) and 40 min (3014 
bpm, P <0.001; Figure 4B). In the CIH group, no significant changes were noted either in the 
amplitude (-16.018.1 and -4.441.8 % from baseline, respectively 20 and 40 min after 
microinjections, P>0.999; Figure 4A) or the frequency of PN bursts (258 and 268 bpm, 
respectively 20 and 40 min after microinjections, P>0.05) after adrenomedullin 
microinjections. In the group of CIH rats that received vehicle in the RVLM, PN burst 
amplitude did not change (-6.016.7 and -11.716.5 % from baseline, respectively 20 and 40 
min after microinjections, P>0.9999; Figure 4A), whilst frequency increased at 20 (325 
bpm, P=0.0027) and 40 min (345 bpm, P=0.0006) after microinjections (Figure 4B).  
Peripheral chemoreflex stimulation potentiates the facilitation of sympathetic activity 
induced by RVLM adrenomedullin in rats exposed to CIH 
When bilateral adrenomedullin in the RVLM was combined with episodic activation 
of peripheral chemoreflex, a long-term sympathoexcitatory effect was observed most 
pronouncedly in CIH versus control groups (Figure 2). We found that mean tSN of control in 
situ preparations (n=6) significantly increased at 20 (37.910.9 % from baseline, P<0.0001; 
Figure 3A) and 40 min (47.015.5 % from baseline, P<0.0001; Figure 3A) after 
microinjections plus peripheral chemoreceptors stimulation. This sympathoexcitatory 
response was associated with increases in tSN mostly during the expiratory phases (E1: 
46.224.6 and 57.337.6 % from baseline; E2: 42.116.9 and 54.725.1 % from baseline, 
respectively 20 and 40 min after microinjections, P<0.05; Figure 3B), although a significant 
but smaller increase was also noted during inspiration (INSP: 25.413.3 and 29.220.8 % 
from baseline, respectively 20 and 40 min after microinjections, P<0.05; Figure 3B). The 
variation of tSN caused by adrenomedullin plus carotid body chemoreceptor stimulation was 
higher during expiration than during inspiration (P < 0.0001).  
In the CIH group (n=6), the evoked SNA response induced by adrenomedullin in the 
RVLM combined with episodic peripheral chemoreflex stimulation was substantially 
magnified relative to response observed in control rats (Figure 2). Already at 20 min after 
microinjections and peripheral chemoreflex stimulations, CIH rats exhibited a significant 
increase in mean tSN activity (61.230.4 % from baseline, P=0.0079; Figure 3A) that was 
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greater than the response observed in control rats (P=0.0491). At 40 min, a further time-
related elevation was noted in the mean tSN activity of CIH rats (149.136.5 % from 
baseline, P<0.0001; Figure 3A), which was larger than in controls (P<0.0001). This 
progressive sympathoexcitatory response of CIH rats was initially (at 20 min) dependent on 
increases in tSN mostly during expiration (E1: 68.755.4 and E2: 87.2109.4 % from 
baseline, P<0.0001; INSP: 27.724.3 % from baseline, P=0.3987; Figure 3C), but later (at 40 
min) due to amplification of tSN activity during all respiratory phases (INSP: 108.082.3, 
E1: 161.569.5  and E2: 177.995.2 % from baseline, P<0.0001, Figure 3C). In CIH rats that 
received microinjections of vehicle in the RVLM combined with episodic activation of 
peripheral chemoreflex (n=5), we found a modest increase in mean (17.06.5 and 21.88.3 % 
from baseline, respectively 20 and 40 min after microinjections, P<0.001; Figure 3A) and in 
respiratory-related tSN activity (INSP: 16.415.3 and 20.220.9, E1: 23.815.5 and 
30.819.0, E2: 10.810.5 and 14.415.7 % from baseline, respectively 20 and 40 min after 
microinjections, P<0.05; Figure 3D). However, the tSN response observed in CIH rats that 
received vehicle in the RVLM were significantly smaller than the responses observed in the 
other groups (P<0.05; Figure 3A).  
Regarding PN activity, adrenomedullin in the RVLM in association with episodic 
stimulation of peripheral chemoreceptors did not alter burst amplitude of all respiratory 
groups (Figure 4A). In the CIH group, we verified that PN burst frequency increased after 
experimental procedures (306 and 326 bpm, respectively 20 and 40 min after 
microinjections, P<0.0036; Figure 4B), whilst no further increase were observed in the 
frequency of the other groups, compared to the values observed before the second round of 
microinjections (Figure 4B).  
Acute peripheral chemoreflex responses after RVLM adrenomedullin in rats exposed to 
CIH 
Intra-arterial KCN injections promoted prompt reflex increases in tSN activity and 
elevated PN frequency in control and CIH groups (Figure 5A). Before any manipulation in 
the RVLM, the magnitude of sympathoexcitatory response to KCN was greater in CIH than 
in control group (∆tSN: 105.629.5 vs control 79.924.7 %, P=0.0480; Figure 5B), whilst the 
tachypnoeic response was equivalent among groups (∆PN: 3111 vs control 2511 bpm, 
P=0.2619; Figure 5D). Bilateral adrenomedullin microinjections in the RVLM did not modify 
the magnitude of the sympathoexcitatory responses in either control or CIH groups (Figure 
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5C). On the other hand, we noticed a consistent increase in the amplitude of tachyponeic 
response of CIH group (P<0.01, Figure 5D), but not in controls (P>0.05). No significant 
changes were noted in the chemoreflex-induced responses in the CIH group that received 
microinjections of vehicle in the RVLM (P>0.05, Figures 5C and E).  
Adrenomedullin receptor antagonism in the RVLM reduces baseline sympathetic activity of 
rats exposed to CIH 
 Microinjections of adrenomedullin receptor antagonist (AM 22-52) in the RVLM of 
control in situ preparations (n=8) did not alter mean tSN activity (66.824.6 vs 60.120.1 
µV, respectively before and 60 min after microinjections, P =0.3170; Figures 6A and B). We 
found variable changes in tSN during the respiratory phases (INSP: 93.411.4, 90.015.7 and 
89.118.6 % from baseline, P>0.05; E2: 101.113.0, 99.014.6 and 95.613.9 % from 
baseline, P>0.05; E1: 103.512.0, 102.533.9 and 100.537.8 % from baseline, P>0.999; 
respectively 10, 30 and 60 min after microinjections, Figures 6C-D) that were associated with 
a reduction in PN burst amplitude (88.010.2, 80.510.2 and 79.010.2 % from baseline, 
respectively 10, 30 and 60 min after microinjections, P < 0.0060; Figure 7A) and an increase 
in PN burst frequency (162 vs 239, 2612 and 2914 bpm, respectively before and 10, 30 
and 60 min after microinjections, P < 0.0015; Figure 7B). In the group of CIH preparations 
(n=7), AM 22-52 microinjections in the RVLM promoted a significant reduction in basal 
levels of mean tSN (83.823.1 vs 63.921.7 µV, P = 0.0024; Figures 6A and B). This 
sympathoinhibitory response to AM 22-52 in the CIH group was associated with reductions 
in tSN during INSP (91.08.4, 81.016.9 and 73.720.4 % from baseline, respectively 10, 30 
and 60 min after microinjections, P < 0.0017; Figure 6C), E2 (91.19.9, 80.412.9 and 
77.710.7 % from baseline, P < 0.0004; respectively 10, 30 and 60 min after microinjections, 
Figure 6D) and during E1 (96.113.7, 86.311.7 and 79.612.6 % from baseline,  
respectively 10, 30 and 60 min after microinjections, P < 0.0412; Figure 6E). Similar to 
control group, a significant reduction in PN burst amplitude (94.98.6, 87.112.9 and 
84.614.4 % from baseline, respectively 10, 30 and 60 min after microinjections, P < 0.0059; 
Figure 7A) and an elevation in PN burst frequency (175 vs 216, 247 and 288 bpm, 
respectively before and 10, 30 and 60 min after microinjections, P < 0.0437; Figure 7B) were 
noted in the CIH group after AM 22-52 microinjections in the RVLM.  
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 With respect to responses to peripheral chemoreceptor stimulation, microinjections of 
AM 22-52 in the RVLM did not modify the magnitude of sympathoexcitatory and 
tachypnoeic responses of control (∆tSN: 19.226.6, 32.139.6 and 5866.0 % from baseline 
response, P> 0.05; ∆PN: 299 vs 2710, 257 and 256 bpm, P>0.9999; respectively 10, 30 
and 60 min after microinjections) and CIH groups (∆tSN: 4.033.8; 9.637.8 and 15.742.5 
% from baseline response, P>0.05; ∆PN: 336 vs 289, 297 and 287 bpm, P>0.05; 
respectively 10, 30 and 60 min after microinjections). 
Histological verification of RVLM microinjection sites 
All effective microinjections were confirmed histologically to be within the RVLM, 
between -12.12 and -12.48 mm relative to Bregma (according to Paxinos & Watson, 2007), 
and occurred at the same area where a prior microinjection of glutamate evoked 
sympathoexcitation (Figure 8). 
 
DISCUSSION 
The major findings of this study are: i) microinjections of adrenomedullin in the 
RVLM of control in situ rat preparations produced a sustained increase in sympathetic 
activity when combined with episodic stimulation of peripheral chemoreceptors; ii) the 
sympathoexcitatory effect of exogenously applied adrenomedullin within the RVLM 
associated with peripheral chemoreceptor stimulation was boosted in rats pre-treated with 
CIH; iii) the antagonism of adrenomedullin receptors in the RVLM reduced significantly 
baseline levels of sympathetic activity only in CIH rats. In contrast, we have no evidence of 
long-term facilitation of respiratory activity using these protocols or its modulation by 
adrenomedullin in RVLM. 
Previous studies by Krukoff and colleagues identified pre-pro-adrenomedullin mRNA 
in areas of the rat central nervous system controlling hypothalamo- neurohypophyseal and 
pituitary axis as well as the RVLM (Shan & Krukoff, 2001a). Subsequent studies by the same 
group reported that adrenomedullin given either intra-cerebroventricularly in conscious 
Sprague-Dawley rats (Shan & Krukoff, 2001b) or microinjected into the RVLM of urethane 
anesthetized Sprague-Dawley rats (Xu & Krukoff, 2004) increased arterial blood pressure 
and heart rate; the latter effects involved glutamate acting on both NMDA and non-NMDA 
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receptors, and release of nitric oxide. Adrenomedullin in the RVLM was also found to inhibit 
the baroreflex, an effect mediated by activation of cAMP-dependent protein kinase A 
pathway (Xu & Krukoff, 2004, 2006). The finding that adrenomedullin in the RVLM 
increased blood pressure in normotensive anesthetized Sprague-Dawley rats (Xu & Krukoff, 
2004) is in stark contrast to the present finding that such a manipulation (using similar 
concentrations of adrenomedullin) failed to change sympathetic activity in normotensive 
Wistar rats studied in situ. This may be explained by differences in the rat strains used and/or 
preparation employed: the in situ rat is decerebrate and unanesthetized and without a 
hypothalamus in contrast to anaesthetised, intact neuraxis in vivo. Alternatively, it may relate 
to a difference in the levels of adrenomedullin within the RVLM between the preparations 
used, and this may link to the presence/absence of the paraventricular nucleus [a region with 
adrenomedullin containing neurones (Shan & Krukoff, 2001a)], level of brainstem perfusion 
[higher in situ than in vivo (Paton, 1996)] and/or the level of oxygenation of the RVLM, as 
described below. However, this all remains to be determined.  
Although adrenomedullin in the RVLM did not change baseline sympathetic outflow, 
the combination of exogenous adrenomedullin with episodic stimulation of peripheral 
chemoreceptor was able promote a persistent increase in mean sympathetic activity of control 
in situ preparations. Interestingly, this sympathoexcitatory response to adrenomedullin plus 
peripheral chemoreceptor activation was associated with an increase of sympathetic activity 
mostly during the expiratory phase. Under resting conditions, sympathetic activity that 
controls vascular resistance shows incrementing respiratory-related bursts during inspiration 
(Malpas, 1998; Zoccal et al., 2009b). During hypoxia, activation of carotid body 
chemoreceptors promotes an increase in sympathetic activity predominantly during the 
expiratory phase, modifying burst pattern (Dick et al., 2004; Moraes et al., 2014; Machado et 
al., 2017). Adrenomedullin microinjections in the RVLM did not potentiate the gain of 
sympathoexcitatory and tachypnoeic responses to chemoreceptor stimulation with KCN (at 
least in the time window we have explored). Based upon that, we suggest that 
adrenomedullin, at concentrations that does not cause acute effects, associated with the 
excitatory inputs triggered by peripheral chemoreceptor inputs, can promote long-lasting 
changes in the excitability of RVLM neurons or modify the strength of synapses on RVLM 
neurons, causing a sustained increase in sympathetic outflow. If this effect of adrenomedullin 
in the RVLM is selective to chemoreceptor inputs or can be engaged by other excitatory 
inputs in the RVLM, is a matter for additional studies.  
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In preparations of CIH rats, adrenomedullin microinjection in the RVLM did not 
cause significant changes in baseline sympathetic activity. On the other hand, the association 
of adrenomedullin with episodic peripheral chemoreceptor stimulation caused a substantial 
time-dependent elevation of sympathetic activity, that was not seen in CIH preparations that 
received vehicle in the RVLM. The adrenomedullin plus chemoreceptor activation-dependent 
elevation in sympathetic activity of CIH rats was associated with amplification of 
sympathetic activity mostly during expiration. Importantly, the antagonism of 
adrenomedullin receptors in the RVLM significantly reduced sympathetic activity of CIH rats 
primarily during inspiration and E2 phase – respiratory periods when sympathetic activity 
was elevated under resting conditions. The decrease in sympathetic activity promoted by AM 
22-52 in the RVLM of CIH rats was associated with reductions in the respiratory drive 
(decrease in PN burst amplitude). The sympathoinhibitory effect of adrenomedullin receptor 
antagonism in the RVLM was not observed in rats that were not exposed to CIH, at least in 
the concentration tested (only a tendency of decrease during inspiration was observed, which 
might be related to reduction in inspiratory drive). Together, these findings indicate that CIH 
exposure sensitizes adrenomedullin-dependent mechanisms in the RVLM neurons (e.g., 
increased number of adrenomedullin receptors, or intracellular signaling facilitation) that, in 
association to augmented chemoreceptor-mediated excitatory inputs (Braga et al., 2006; 
present study), can produce amplified and long-lasting sympathoexcitatory effects, 
contributing to chronically elevate arterial pressure levels (Zoccal et al., 2007; Zoccal et al., 
2008).  
Our previous work has proposed that the brainstem of both the spontaneously 
hypertensive rat (Paton et al., 2009; Cates et al., 2011; Marina et al., 2015) and humans with 
hypertension (Warnert et al., 2016) are chronically hypoperfused and may become hypoxic if 
arterial pressure falls, as it can do during sleep. This is relevant because hypoxia is a major 
stimulus for releasing adrenomedullin (Serrano et al., 2002a; Serrano et al., 2002b; Ji et al., 
2005) and is one of the few genes that can be neuroprotective to the brain (Bernaudin et al., 
2002). Indeed, adrenomedullin has been associated with the induced protection of remote 
preconditioning thereby reducing ischemia-reperfusion injury (Dong et al., 2018); the latter 
was dependent upon activation of hypoxia inducible factor 1. Integrating this previous 
evidence with the data from the present study, we propose that during CIH exposure, the 
central hypoxia combined with the activation of peripheral chemoreceptors might cause the 
release of adrenomedullin into the RVLM causing long-term facilitation of sympathetic 
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activity. This process may itself constitute part of the neuroprotective mechanism to ensure 
preserved or elevated cerebral blood flow due to the elevated arterial blood pressure resulting 
from increased vasoconstrictor sympathetic activity. This neurally mediated mechanism has 
been termed the selfish brain hypothesis of hypertension and negates low blood oxygen 
within the brainstem (Paton et al., 2009; Cates et al., 2011; Marina et al., 2015; Warnert et 
al., 2016). 
A question prompted is where might the endogenous adrenomedullin originate? 
Whilst we do not rule out release from neurones located within the RVLM, the hypothalamus 
in both rats (Ueta et al., 1995; Ueta et al., 1999; Shan & Krukoff, 2001a) and humans (Satoh 
et al., 1996) has been shown to contain neurons expressing adrenomedullin including the 
paraventricular nucleus that is known to project to the RVLM (Cato & Toney, 2005). 
Whether paraventricular-RVLM projecting neurones contain adrenomedullin and if they play 
an endogenous role in the hypertension caused by CIH in rats remains to be established. 
Although adrenomedullin in the RVLM in combination with peripheral 
chemoreceptor stimulation caused long-term facilitation of baseline sympathetic activity, the 
amplitude of sympathoexcitatory reflex response to KCN was not potentiated in both groups. 
In contrast, the magnitude of KCN-induced tachypnoeic reflex response (dependent on a 
reduction in expiratory time) was amplified in CIH rats, indicating that adrenomedullin in the 
RVLM enhanced the central gain of peripheral chemoreflex, affecting mainly the 
mechanisms that control breathing during hypoxia. This effect may involve the respiratory 
neurons of Bötzinger and pre-Bötzinger complexes that co-exist with pre-sympathetic 
neurons in the ventrolateral medulla (Moraes et al., 2012). The fact that this adrenomedullin-
induced respiratory effect did not impact on the sympathoexcitatory reflex response to KCN 
suggests that the effects of ADM on RVLM neurons might be selective to neurones that are 
responsible for the generation of baseline sympathetic activity rather than neurones that are 
responsive to reflex inputs, or to specific RVLM neuronal phenotypes (e.g. catecholaminergic 
vs non-catecholaminergic) that exhibit differential projection targets (Ross et al., 1984a; 
Haselton & Guyenet, 1989; Aicher et al., 1996; Li & Guyenet, 1997; Abbott et al., 2012; 
Abbott et al., 2013). These hypotheses await confirmation. 
 
Perspectives 
Previous GWAS using a multi-stage design in 200,000 individuals of European ancestry 
described 29 SNPs associated with systolic and diastolic blood pressure, and hypertension. 
One of these SNPs was the adrenomedullin gene (International Consortium for Blood 
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Pressure Genome-Wide Association et al., 2011). Given the work of Krukoff and colleagues 
(see above) and the present data, it is tempting to speculate that analogous mechanisms to 
those described herein may occur in the human brainstem in the aetiology of neurogenic 
hypertension. One relevant group of human patients are those with sleep apnoea. In this 
condition, the apnoeas cause a cyclical activation of peripheral chemoreceptors and central 
hypoxia producing sustained and elevated sympathetic activity with hypertension (Somers, 
1995; Narkiewicz et al., 1998). It now becomes important to understand the role of 
adrenomedullin in the human RVLM for the generation of excessive sympathetic activity in 
sleep apnoea and whether this might be a putative clinical target. Further work is needed to 
define the receptor type involved, which is challenging: there are two forms of 
adrenomedullin in mammals - AM1 and AM2. AM2 is also known as intermedin. 
Adrenomedullin signals through a unique G-protein coupled receptor - the Calcitonin 
receptor-like receptor (CLR) (Poyner et al., 2002). CLR functions as a calcitonin gene–
related peptide (CGRP) receptor or an AM receptor depending on the expression of specific 
receptor activity–modifying proteins (RAMPs) of which there are three (Brain & Grant, 
2004). Thus, it becomes necessary to define the presence and function of receptors and 
RAMPs to fully understand the potential of therapeutic intervention in diseases in which 
adrenomedullin may work in concert with intermittent peripheral chemoreceptor input in 
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FIGURE LEGENDS 
 
Figure 1. Baseline sympathetic activity of CIH-treated rats. Panel A: Representative raw 
and integrated (∫) recordings of baseline thoracic sympathetic (tSN) and phrenic (PN) nerve 
activities of in situ preparations from control and CIH pre-treated rat groups. Panel B: 
Average values of tSN activity during inspiration (Insp), first stage of expiration (E1) and 
second stage of expiration (E2) of control (n=6) and CIH (n=6) in situ rat preparations. * 
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Figure 2. Adrenomedullin in the RVLM of control and CIH-treated rats. Representative 
raw and integrated (∫) recordings of thoracic sympathetic (tSN) and phrenic (PN) nerve 
activities of in situ preparations of control and CIH pre-treated rats during baseline (left), 
after bilateral microinjections of adrenomedullin (100 fmol/100 nl) in the RVLM (middle) 
and after combined bilateral microinjections of adrenomedullin in the RVLM (100 fmol/100 
nl) and following episodic stimulation (5 times every 5 min) of peripheral chemoreceptors 







This article is protected by copyright. All rights reserved. 
Figure 3. RVLM microinjections of adrenomedullin evoked increases in sympathetic activity of CIH-
treated rats. Panel A: changes in mean thoracic sympathetic activity (tSN), relative to baseline 
before microinjections (100%), elicited by bilateral exogenous adrenomedullin (ADM, 100 fmol/100 
nl) or vehicle in the RVLM, either alone or in combination with episodic peripheral chemoreceptor 
stimulation  (5 times every 5 min), of control (n=6) and CIH (n=5-6) in situ rat preparations. * 
different from respective baseline; # different from control group and † different from CIH + vehicle 
group (P<0.05). Panels B-D: average changes in tSN during inspiration (Insp), first stage of expiration 
(E1) and second stage of expiration (E2) of control and CIH groups that received adrenomedullin 
microinjections in the RVLM (Panels B and C), and of CIH group that receive vehicle microinjections 
in the RVLM (Panel D). * different from respective baseline; # different from 20 and 40 min after 
adrenomedullin in the RVLM; and φ different from 20 min after adrenomedullin in the RVLM + 
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Figure 4. Baseline phrenic nerve activity in control and CIH-treated rats after 
adrenomedullin microinjections in the RVLM. Average values of baseline phrenic (PN) 
burst amplitude (Panel A) frequency (Panel B) of control (n=6) and CIH (n=6 and 5) in situ 
rat preparations before and after bilateral microinjections of adrenomedullin (100 fmol/100 
nl) or vehicle in the RVLM, before and after repetitive stimulation (5 times every 5 min) of 
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Figure 5. Adrenomedullin microinjections in the RVLM do not modify the acute 
chemoreflex sympathoexcitatory response of in situ rat preparations. Panel A: 
representative raw and integrated (∫) responses of thoracic sympathetic (tSN) and phrenic 
(PN) nerve activities of control (upper panels) and CIH groups (lower panels) following 
peripheral chemoreceptor activation with KCN (arrows) before and after (5
th
 stimulation) 
bilateral RVLM microinjection of adrenomedullin (100 fmol/100 nl). Panel B: magnitude of 
chemoreflex-induced increase (∆) in the tSN activity (before microinjections) of control 
(n=6) and CIH-treated groups that received adrenomedullin in the RVLM. * different from 
respective baseline (P<0.05). Panel C: changes in the magnitude of chemoreflex-induced 
sympathoexcitatory response (relative to the response before microinjections in the RVLM) 
in control (n=6) and CIH-treated groups that received adrenomedullin, or of CIH-treated 
group (n=5) that received vehicle in the RVLM. Panels D and E: magnitude of tachypnoeic 
response (∆PN) to peripheral chemoreceptor stimulation in control and CIH groups, before 
(Panel D) or after either adrenomedullin or vehicle injections in the RVLM (Panel E).  
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Figure 6. Adrenomedullin receptor antagonism in the RVLM reduces baseline 
sympathetic activity of in situ preparations of CIH rats. Panel A: raw and integrated (∫) 
tracings of thoracic sympathetic (tSN) and phrenic (PN) nerve activities of control (upper 
panels) and CIH (lower panels) in situ preparations, representative from their groups, 
illustrating the effects of bilateral microinjections of AM 22-52 (100 pmol/100 nl) in the 
RVLM on baseline parameters. Panel B: mean tSN activity of control (n=8) and CIH (n=7) 
in situ preparations before and 60 min after bilateral microinjections of AM 22-52 in the 
RVLM. Panels C-E: changes in tSN activity (relative to baseline activity before 
microinjections) during inspiration (Insp, Panel C), first stage of expiration (E1, Panel D) and 
second stage of expiration (E2, panel E) of control and CIH groups after microinjections of 
AM 22-52 in the RVLM. * different from respective baseline (P<0.05). 
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Figure 7. Effects of adrenomedullin receptor antagonism in the RVLM on phrenic 
activity of in situ rat preparations of control and CIH groups. Average values of baseline 
phrenic nerve (PN) burst amplitude (Panel A, relative to values before microinjections) and 
frequency (Panel B) before and after bilateral microinjections of AM 22-52 in the RVLM of 
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Figure 8. Functional and histological confirmation of adrenomedullin microinjections in 
the RVLM. Panel A: Raw and integrated (∫) responses of thoracic sympathetic (tSN) and 
phrenic (PN) nerve activities evoked by L-glutamate (1 nmol/100 nl) microinjected 
unilaterally in the RVLM of an in situ rat preparation. Panel B: Representative 
photomicrograph of a coronal section illustrating the microinjections made within the RVLM 
as indicated by the presence of green fluorescence beads in this region (upper panel). In the 
schematic drawing are indicated the approximate location of the centre of all microinjections 
performed in the RVLM.  
 
 
 
